Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Queen Mary and King Frederik are caught in a royal Photoshop row
Nepo baby Christian Wilkins poses with Kylie Minogue as he attends her Las Vegas residency
Tragedy as Taylor Swift fan dies days before her 10th birthday
Paris Olympic athletes to feast on freshly baked bread, select cheeses and plenty of veggie options
Angels score two on wild pitch and throwing error, beat Phillies 6
Thiago Silva, 39, breaks down in tears as he announces he is leaving Chelsea
Select list of nominees for 2024 Tony Awards
New Jersey seeks fourth round of offshore wind farm proposals as foes push back
Vicky McClure cuts a stylish figure in a red velvet suit as she and co